Dutch DNA labelling firm Kreatech raises funds
This article was originally published in Clinica
Kreatech Biotechnology of Amsterdam, the Netherlands, has raised E6m ($6.5m) in a third round of equity funding led by 3i and including Life Science Partners of the Netherlands and Germany, and Alafi Capital of the US. Kreatech's specialism is the labelling of nucleic acid and proteins. It intends to direct the funds towards its development programmes, as well as setting up US sales and support operations.